|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013227,
umls-concept:C0018418,
umls-concept:C0024902,
umls-concept:C0025266,
umls-concept:C0032105,
umls-concept:C0039286,
umls-concept:C0087111,
umls-concept:C0199176,
umls-concept:C0290883,
umls-concept:C0376358,
umls-concept:C0441889,
umls-concept:C1166397,
umls-concept:C2603343
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2005-7-27
|
|
pubmed:abstractText |
A randomized multicenter (14 centers) trial was conducted in 114 men with prostate cancer to determine whether the antiestrogen tamoxifen ('Nolvadex') 20 mg or the aromatase inhibitor anastrozole ('Arimidex') 1 mg prevent gynecomastia and breast pain during treatment with the non-steroidal antiandrogen bicalutamide ('Casodex') 150 mg, without compromising efficacy, safety, or quality of life. Plasma samples were collected in a subgroup of these patients to investigate whether trough (pre-dose) concentrations of bicalutamide 150 mg are influenced by concomitant administration of tamoxifen 20 mg or anastrozole 1 mg; the results of this pilot study are reported in this article.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Androgen Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Anilides,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal,
http://linkedlifedata.com/resource/pubmed/chemical/Aromatase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Nitriles,
http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen,
http://linkedlifedata.com/resource/pubmed/chemical/Tosyl Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Triazoles,
http://linkedlifedata.com/resource/pubmed/chemical/anastrozole,
http://linkedlifedata.com/resource/pubmed/chemical/bicalutamide
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0344-5704
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
56
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
415-20
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15838655-Aged,
pubmed-meshheading:15838655-Aged, 80 and over,
pubmed-meshheading:15838655-Androgen Antagonists,
pubmed-meshheading:15838655-Anilides,
pubmed-meshheading:15838655-Antineoplastic Agents, Hormonal,
pubmed-meshheading:15838655-Aromatase Inhibitors,
pubmed-meshheading:15838655-Chromatography, High Pressure Liquid,
pubmed-meshheading:15838655-Double-Blind Method,
pubmed-meshheading:15838655-Drug Interactions,
pubmed-meshheading:15838655-Gynecomastia,
pubmed-meshheading:15838655-Humans,
pubmed-meshheading:15838655-Male,
pubmed-meshheading:15838655-Middle Aged,
pubmed-meshheading:15838655-Nitriles,
pubmed-meshheading:15838655-Pain,
pubmed-meshheading:15838655-Prostatic Neoplasms,
pubmed-meshheading:15838655-Tamoxifen,
pubmed-meshheading:15838655-Tosyl Compounds,
pubmed-meshheading:15838655-Triazoles
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
|
|
pubmed:affiliation |
Professorial Unit of Medical Oncology, University and National Cancer Research Institute, Largo R. Benzi 10, 16132, Genoa, Italy. francesco.boccardo@istge.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|
